CONVINCE trial reveals the effect of long-term colchicine on recurrent stroke and cardiovascular events

FHS
May 16, 2024
5:39 pm

In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organisation Conference (ESOC) 2024, anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke in the primary intention-to-treat analysis.

Jim Wilson’s GemmaBio raises $34M to commercialize gene therapies for rare diseases

GemmaBio, a company founded by gene therapy pioneer Jim Wilson, has raised $34 million in seed funding to try and resuscitate the floundering gene therapy

December 25, 2024

Gut microbiota imbalance linked to higher UTI risks in women

Study reveals that gut microbial dysbiosis and frequent antibiotic use are key risk factors for recurrent urinary tract infections (UTIs) in women, emphasizing the importance

June 7, 2024

Mayo Clinic research shows health benefits of active workstations

A recent Mayo Clinic study suggests that active workstations incorporating a walking pad, bike, stepper and/or standing desk are successful strategies for reducing sedentary time

April 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.